This page shows the latest Lupin news and features for those working in and with pharma, biotech and healthcare.
In September 2019, the German drugmaker also made a $720m play for a MEK inhibitor from India’s Lupin that it is looking to pair with its stable of KRAS inhibitors. ... The Lupin deal came only a few short weeks after Boehringer partnered with The
Signs of progress in the field are emerging. Boehringer Ingelheim has licensed a MEK inhibitor from India’s Lupin that it intends to pair with its stable of KRAS inhibitors, a ... For Lupin, Boehringer is the second big biopharma partner for its
Earlier this month Indian drugmakers Lupin Labs and Shilpa Medicare both won tentative FDA approval for generic dimethyl fumarate capsules, although they have not indicated when they intend to place the
The patent was opposed by the Indian Pharmaceutical Alliance (IPA), a trade organisation representing India's larger pharmaceutical companies, including Cipla, Dr Reddy's Labs, Lupin, Nicholas Piramal, Ranbaxy and Wockhardt.
Other notable M&A activity in the sector includes Par Pharma's $490m deal to buy JHP Pharmaceuticals in January, Lupin Laboratories' agreement to buy Nanomi of the Netherlands the following
The generics companies implicated in the scandal - Niche/Unichem, Matrix (part of Mylan), Teva, Krka and Lupin - are facing penalties of 97m between them.
More from news
Approximately 2 fully matching, plus 24 partially matching documents found.
165. Shionogi (JP). Kyowa (JP) (Lupin). Asset acquisition Japan. 21 branded products in Japan with $90m sales.
The consolidation in the generics industry has also increased with Lupin's acquisition of the US generics company Gavis for $880m at a high sales multiple of nine but which has ... In July Lupin also acquired a factory in Russia and a speciality product
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Dr Uwe Meya joins from Lupin Atlantis Holdings. Spanish orphan disease specialist Minoryx Therapeutics has appointed Dr Uwe Meya as its new chief medical officer. ... He joins the Barcelona-based drug development company from Lupin Atlantis Holdings,
He moves to the company from Vifor. Mumbai-based pharma company Lupin has appointed Thierry Volle to lead its Europe, Middle-East and Africa operations as president. ... Vinita Gupta, Lupin's chief executive officer, said: "We are delighted to have
He will join the company next week from Lupin where he was a group president with an inhalation remit for Europe, Russia &CIS. ... We are impressed by the extensive experience of Mr Chagnaud, gained in international companies such as Merck Generics, Teva
Theresa Stevens has experience at Novartis and Aptalis. Lupin has appointed Theresa Stevens as chief corporate development officer for its global operations. ... Lupin's decision to hire Stevens follows its appointment earlier this year of Teva's Dr
countries. He will also be responsible for developing Lupin's core strategy for inhalation across all developed markets. ... Prior to joining Lupin, Dr Chagnaud was senior VP, Central and Eastern Europe, at Israel-based Teva.
More from appointments
Approximately 3 fully matching, plus 2 partially matching documents found.
For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...